NextPoint is a biotechnology company that is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA pathway. They are developing a new class of monotherapies for patients who will not benefit from PD-1/L inhibitors. Their team of proven drug developers is working to deliver a new class of monotherapies for patients who will not benefit from PD-1/L inhibitors.
However, they have recently announced that Axel Hoos, MD, PhD has joined NextPoint Therapeutics Board of Directors.
Employees: 11-50
Total raised: $122.5M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | BioImpact ... | bioimpactc... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.02.2024 | Series B | $122.5M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 15.02.2024 | NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series ... | NextPoint Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing a new ... | finsmes.co... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia... | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital fl... | fiercebiot... |
| 10.01.2023 | NextPoint Therapeutics Announces $80 Million Series B Financ... | - | bioimpactc... |
| - | NextPoint Therapeutics Closes $42.5 Million To Develop New C... | NextPoint Therapeutics – a clinical-stage biotechnology company developing a new class of precision ... | pulse2.com... |
| - | NextPoint Therapeutics | “NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pi... | fastfounde... |